Phase I/II Trial: BIBF 1120 Added to Low-dose Cytarabine in Elderly Patients With Acute Myeloid Leukemia (AML)
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Low-dose cytarabine works in a minority of elderly patients with an acute myeloid
leukemia unfit for intensive induction therapy by killing of leukemia cells. Addition of
BIBF1120 to low-dose cytarabine might enhance the killing of leukemia cells.
PURPOSE: This phase I / II trial is studying how safe BIBF1120 can be combined with low-dose
cytarabine (phase I) and how well the combination of low-dose cytarabine and BIBF1120 works
in elderly patients with acute myeloid leukemia unfit for intensive chemotherapy (phase II).